Viridian Therapeutics, Inc. VRDN
NASDAQ · United States · Health Technology
$18.99-1.60 (-7.77%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
These ratios divide the lines in the statements below by the current price; both inputs of every value are visible on this page. The P/E on the overview comes from the same calculation. P/E and P/S are left blank for loss-making companies or where revenue is not reported. Not investment advice.
| LTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | $71.13M | $70.85M | $302.00K | $314.00K | $1.77M | $2.96M |
| Revenue growth (YoY) | — | +23,359.9% | -3.8% | -82.3% | -40.2% | — |
| Operating expenses | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Operating Income | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Operating margin | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| EBITDA | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Income tax | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Net Income | -$386.97M | -$342.60M | -$269.95M | -$237.73M | -$129.87M | -$79.41M |
| Net margin | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Diluted EPS | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Diluted shares | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| LTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & equivalents | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Current Assets | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Assets | $1.10B | $899.42M | $742.40M | $490.42M | $435.09M | $203.71M |
| Total Current Liabilities | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Liabilities | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total debt | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Equity | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| LTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -$333.34M | -$276.39M | -$232.32M | -$184.17M | -$93.84M | -$54.58M |
| Capital expenditure | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Free cash flow | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Cash from Investing | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Cash from Financing | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
Taken from the company's own 10-K and 10-Q filings via the SEC's XBRL data service. The "LTM" column is the last completed fiscal year plus the current year to date, minus the same period a year earlier. Lines a company tags with a non-standard label are left blank rather than filled with an approximation. Not investment advice.